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Both systemic lupus erythematosus (SLE) and vitiligo are autoimmune disorders that have strong evidence of complex
genetic contributions to their etiology, but, to date, efforts using genetic linkage to find the susceptibility genes for
either phenotype have met with limited success. Since autoimmune diseases are thought to share at least some of
their genetic origins, and since only a small minority (16 of 92) of the European-American pedigrees multiplex for
SLE in our collection have one or more affected members with vitiligo, we hypothesized that these pedigrees might
be more genetically homogeneous at loci important to both SLE and vitiligo and, hence, have increased power for
detection of linkage. We therefore evaluated genomewide microsatellite-marker–scan data for markers at an average
marker density of ∼11 cM in these 16 European-American pedigrees and identified a significant linkage at 17p13,
where the maximum multipoint parametric LOD score was 3.64 ( ) and the nonparametric linkage55P ! 4.3# 10
score was 4.02 ( ), respectively. The segregation behavior of this linkage suggests a recessive mode55P ! 2.8# 10
of inheritance with a virtually homogeneous genetic effect in these 16 pedigrees. These results support the hypotheses
that SLE and vitiligo may share important genetic effects and that sampling on the basis of clinical covariates
dramatically improves power to identify genetic effects.
Multiple genes characterize the etiology of complex ge-
netic traits, with alleles at any single susceptibility gene
making only small-to-moderate contributions to the to-
tal risk (Lander 1996; Chakravarti 1999). In this model,
susceptibility alleles have low penetrances and are com-
mon in the general population, with no single allele being
necessary or sufficient for clinical disease. This makes
their identification difficult, requiring analysis of large
numbers of multiplex families.More specifically, the vast
majority of families ascertained through an affected pro-
band will have no other affected member, when the dis-
ease is actually caused by the epistatic interaction of two
or more recessive loci (Majumder and Nath 1992; Ma-
jumder 1993). Moreover, various combinations of con-
tributing alleles at multiple genes in individual patients
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may result in disease phenocopies. Consequently, finding
genetically homogeneous multiplex families for such a
disease phenotype is very difficult.
However, there have been a few notable successes in
the identification of complex disease genes by grouping
of families according to clinical covariates. An association
with a lower age at onset, which segregates in aMendelian
fashion, can lead to gene identification by classic posi-
tional cloning methods, such as that achieved for the
breast-ovarian cancer gene BRCA1 (Miki 1994; Wooster
1995). Stratification based on the presence of at least one
case of the follicular variant of papillary thyroid carci-
noma has provided very convincing evidence of linkage
to 2q22 (McKay et al. 2001). The principal aim behind
this method of grouping of families is to achieve a sample
of families with a high degree of genetic and clinical ho-
mogeneity. Sample heterogeneity may also be reduced ei-
ther by use of narrower inclusion criteria or by selection
on the basis of special traits that are shared among the
families. Identification of traits that tend to be shared by
family members—particularly by affected individuals—is
a means of identification of useful subgroups of families
and may identify traits that share common genetic com-
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ponents. With this in mind, we considered families seg-
regating for systemic lupus erythematosus (SLE) (MIM
152700) and vitiligo (MIM 193200), both apparently au-
toimmune disorders.
SLE is a complex disease in which humoral immune
responses are directed against a multitude of self-antigens.
Both environmental and genetic factors are involved in
the pathogenesis. Evidence for a genetic basis is estab-
lished through significant familial aggregation, with a
7%–12% increased risk in the first- or second-degree rel-
atives of a proband (Vyse and Todd 1996); an increased
concordance rate in identical twins (15%–69%) as op-
posed to dizygotic twins (2%–5%) (Deapen et al. 1992);
and genome scans showing moderate support for genetic
linkage (Gaffney et al. 1998, 2000; Moser et al. 1998;
Gray-McGuire et al. 2000; Lindqvist et al. 2000; Mag-
nusson et al. 2000). Recently, Meng et al. (1996) esti-
mated the heritability of SLE at 57% in a Chinese data
set. The relative risk ratio for the sibs of an affected pro-
band is ∼15. Significant gender differences are observed
in prevalence, age at onset, premorbid conditions, clinical
expression, course of illness, response to treatment, and
morbidity risk (Hochberg 1997; Lawrence et al. 1998).
In addition, there are also important racial differences in
disease manifestations (Petri 1998). In all likelihood, SLE
is a genetically heterogeneous disease.
Vitiligo is an autoimmune dermatological disorder
characterized by hypopigmentary patches that tend to be-
come progressive over time (Larner 1959; Nordland
1987). The prevalence of this disorder is ∼1% in the
United States (Larner 1959; El-Mofty 1968) and ∼0.38%
inDenmark (Howitz et al. 1977). Although theprevalence
of vitiligo varies significantly with age, the age-specific
prevalence rates are not significantly different between
genders (Das et al. 1985; Majumder et al. 1993). Familial
(Majumder et al. 1988; Nath et al. 1994) and twin (Sie-
mens 1953) studies have shown significant evidence for
familial aggregation and have suggested a genetic basis.
Although vitiligo aggregates in families, it does not appear
to segregate in a simple Mendelian pattern and, like SLE,
has a complex genetic etiology. An oligogenic model for
vitiligo was proposed by Majumder et al. (1988) and was
cross-validated by Nath et al. (1994, 1995). No genome-
scan studies on vitiligo have been reported.
SLE shows familial cosegregation with other auto-
immune diseases, such as rheumatoid arthritis, Sjogren
syndrome, anti-phospholipid antibody syndrome, scle-
roderma, and autoimmune thyroid disease. In fact, stud-
ies show that 10%–20% of lupus probands have at least
one first- or second-degree relative afflicted with an au-
toimmune disease other than lupus.
Empirical evidence is consistent with the existence of
many SLE-susceptibility genes, usually of low penetrance,
and there is similar, although separate, evidence with
regard to the genetics of vitiligo. The expectation is that,
when families are selected as segregating for both phe-
notypes (by any one of a large number of possible strat-
egies), then there should be increased power to detect
what should be a very small number of susceptibility
genes.
To evaluate evidence of genetic linkage in families with
vitiligo-related SLE, we identified 16 families of Euro-
pean-American origin that were selected on the basis of
the presence of at least one case of vitiligo from the col-
lection of 92 multiplex pedigrees with European-Ameri-
can ancestry, ascertained in our ongoing SLE genetic-link-
age projects. Most of the time vitiligo was diagnosed on
the basis of review of medical records. Fourteen (87%)
of the families with SLE and vitiligo were nuclear families.
Among these 16 families, there were 41 individuals af-
fected with SLE (the average number of affected individ-
uals per family was 2.5), 20 individuals affected with
vitiligo, and 14 individuals affected with both vitiligo and
SLE. A total of 95 individuals from these 16 families were
used in the analyses. In the linkage analyses, we consid-
ered only those individuals with SLE as being af-
fected—that is, those with only vitiligo were considered
to be unaffected.
Genomic DNA was isolated from peripheral blood
cells, buccal cell swabs, or Epstein-Barr virus–transformed
cell lines by standard methods. Methods for genotyping
of families have been described elsewhere (Moser et al.
1998; Gray-McGuire et al. 2000). A total of 318 micro-
satellite markers with an average heterozygosity of 76%
(range 56%–94%) were typed. Average marker spacing
was 11 cM (range 2–30 cM). Prior to any linkage anal-
yses, all family relationships were confirmed byRELTEST
(Olson 1999).
Since the disease model (which considered mode of
inheritance, disease-allele frequency, and penetrances of
genotypes at the disease locus) was uncertain, we initially
screened the entire genome, using the nonparametric
linkage analysis program GENEHUNTER-PLUS, which
allows complete multipoint analysis with a large num-
ber of highly polymorphic markers. GENEHUNTER-
PLUS incorporates both traditional parametric (i.e.,
LOD scores, under the assumption of assuming genetic
homo- or heterogeneity) and nonparametric linkage
analysis (Zlr scores, assessed by comparison of the ob-
served setwise IBD sharing among all affected family
members versus that expected under the null hypothesis
of no linkage) (Kruglyak et al. 1996; Kong and Cox
1997). We chose equal weight for each family and chose
the Sall scoring function to allow comparison of observed
IBD allele sharing among all the affectedmembers versus
that expected under the null hypothesis of random seg-
regation. From the Zlr score, the nonparametric LOD
score is calculated as /2ln(10), which is comparable2Z lr
to the parametric model–based LOD score. We esti-
mated marker-allele frequencies in family founders by
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Figure 1 Multipoint model-free (Zlr score) and model-based (LOD score) linkage, for chromosome 17 in families with vitiligo-related
SLE. Marker positions are denoted by the vertical tic marks; the marker order, from left to right, is D17S1303-D17S1998-D17S974-D17S1303-
D17S2196-D17S1294-D17S1299-D17S2180-D17S1290-D17S2193-D17S1301-D17S784-D17S928.
using FASTLINK (Cottingham et al. 1993). Marker map
positions were obtained from the latest available sex-
averaged maps from theMarshfield database (Center for
Medical Genetics, Marshfield Medical Research Foun-
dation). Once we observed, on the basis of the nonpara-
metric method, significant evidence of linkage, we then
estimated the disease model at that region bymaximizing
the model parameters under the constraint that the es-
timated SLE prevalence be considered to be !0.1%.
The nonparametric analysis revealed significant evi-
dence of linkage ( , ) between5Z p 4.02 Pp 2.8# 10lr
the markers D17S974 and D17S1298. On the basis of
this Zlr score, the estimated nonparametric LOD score
was calculated to be 3.5. We maximized the parameters
to obtain the most parsimonious model at this locus, by
parametric linkage analysis. The highest LOD score was
3.64 at the position matching that of the peak Zlr score
(fig. 1). The most parsimonious model was a moderately
common, recessively inherited gene with 16% penetrance
in the recessive homozygote and with a disease-allele fre-
quency of .025. When the 1-unit-stepdownmethod (Con-
neally et al. 1985) was used, the 95% support interval
for the linked region for the location of the putative sus-
ceptibility gene was ∼23 cM, on the basis of the result of
parametric analysis and the most parsimonious model.
We investigated the genetic heterogeneity by calculating
Hlod, the LOD score under a heterogeneity model; the
estimated proportion of families linked to this locus was
essentially 100%, and theHlod scorewas almost the same
as the .65 under a homogeneity model. Under a dominant
model, the highest LOD score obtained was .02, which
was significantly different from the LOD score estimated
under a recessive model ( , 1 df,2x p 16.7 Pp 4.5#
). We also performed an affecteds-only parametric510
analysis, by recoding the unaffected individuals as un-
known, so that the LOD score would not be affected by
the penetrance function. The results were essentially un-
changed (LOD score 3.67).
There are two diagnostic caveats to consider with re-
gard to this study’s assessment of vitiligo. First, vitiligo
clinically is diagnosed as lesionswith loss of pigmentation.
Any condition that destroys the melanocytes of the skin
without leaving a scar or other evidence of a different
process will, to the eye of the ordinary clinical examiner,
be indistinguishable from vitiligo. In this study, our as-
certainment of vitiligo relied on the reports of routine
medical examinations. To our knowledge, no skin biop-
sies were done to confirm the diagnosis of vitiligo. Fur-
thermore, in some of these cases the lesions are being
assessed remotely in time, long after the active process
that created them. A skin biopsy done at this time would
not likely be informative beyond indicating the absence
of melanocytes.
Second, in SLE, the discoid rash, particularly in pa-
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tients requiring profound immunosuppression, may re-
solve, leaving hypopigmented lesions that cannot be dis-
tinguished from vitiligo and that might be referred to as
“vitiligo” by the physician. The pathology of the discoid
rash is fundamentally different than that of ordinary
vitiligo, and so this is a potentially confounding ascer-
tainment issue. Among the 20 patients affected with vit-
iligo, only 1 was diagnosed with discoid lesions. Since
discoid rash is much more prevalent in African Ameri-
cans with SLE than in European Americans with SLE,
one would expect that African-American pedigrees may
be more susceptible by this problem. Indeed, we did not
find any linkage effects in the six African-American ped-
igrees multiplex for SLE and containing an individual
affected with vitiligo when they were evaluated as de-
scribed above for the European-American pedigreesmul-
tiplex for SLE (data not shown). However, there are
probably too few pedigrees to allow us make a definite
conclusion.
Our finding suggesting genetic commonality between
some cases of SLE and some cases of vitiligo brings the
molecular mechanisms of two quite different autoimmune
processes together. SLE is thought of as a largely humoral
autoimmune process, particular in its effector mecha-
nisms, and is a systemic autoimmune disorder. Much of
the disease specificity and abnormalities focus on the B
lymphocyte. Indeed, there are even data suggesting a role
for Epstein-Barr virus as an environmental risk factor in
this disease (James et al. 1997, 2001). Patients with SLE
are always symptomatic and, if left untreated, usually
have a life-threatening immune-destructive disease pro-
cess. On the other hand, the melanocyte destruction of
vitiligo proceeds asymptomatically, except for the hypo-
pigmentation. This is a prototypic organ-specific auto-
immune disorder. There is a report that vitiligo may be
triggered by a cytomegaloviral infection in some patients
(Grimes et al. 1996). Although autoantibodies have been
found, the current paradigm for vitiligo as found in the
general population is that it is mediated by melanocyte-
specific T lymphocytes (Ogg et al. 1998; Li et al. 2000).
Whether, in these pedigrees multiplex for SLE, the indi-
viduals who are affected with vitiligo evidence a hypo-
pigmentation mechanism similar to that described for the
ordinary sporadic cases of vitiligo is not yet known.
The outcome of this experiment is provocative and has
led to a search for possible candidate genes for further
study. There are several potentially interesting candidate
genes located within this genomic region that are partic-
ularly related to either immune response or dermatologic
traits; these include the gene for retinitis pigmentosa 13
(RP13), the gene for T-cell immunodeficiency, the gene
for congenital alopecia (WHN), the gene for non–insulin-
dependent diabetes mellitus (SLC2A4), the gene for my-
asthenia gravis (MGI), and the gene for homeobox B9
related to breast cancer. Any one of these candidate
gene(s) has the potential for causal mutation(s).
In summary, we have identified a potentially infor-
mative genomic region at 17p13, which may contain the
putative gene, SLEV1, for vitiligo-related SLE. Here we
would like to emphasize that the main phenotype used
for the linkage analysis was SLE; so, the linkage to the
17p region reflects a gene predisposing to SLE. Never-
theless, since the presence of vitiligo in the family was
used as a pedigree-ascertainment criterion, and since vit-
iligo and SLE may be associated, it is possible that SLE
and vitiligo may have some common autoimmune ge-
netic determinant(s). Alternatively, we may assert that
there is a gene that leads primarily to developing SLE
and that, at least among the ascertained families, also
modifies the risk for vitiligo. From this study, it is also
evident that, regardless of the actual number of genes
involved in SLE, decreasing the sample heterogeneity by
subgrouping the families on the basis of common as-
sociated traits has increased the likelihood that genes for
SLE will be identified; in fact, to our knowledge, this
result is one of the few more-convincing SLE-linkage
results published to date.
Acknowledgments
We thank the study participants for their help with this re-
search effort. S.K.N. sincerely thanks Prof. P. P. Majumder for
his helpful discussions and suggestions. We also thank the two
anonymous reviewers for their helpful comments. This study
was supported by National Institutes of Health grants AR-1-
2253, AI24717, AR42460, AR45231, AI31584, and RR15577.
Some of the results presented herein were obtained by the pro-
gram package of S.A.G.E., supported by U.S. Public Health
Services Resources grant RR03655 from the National Center
for Research Resources. Ten of the families were obtained from
the Lupus Multiplex Registry and Repository (grant AR-1-
2253).
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Center for Medical Genetics, Marshfield Medical Research
Foundation, http://research.marshfieldclinic.org/genetics/
Lupus Multiplex Registry and Repository, http://omrf.ouhsc
.edu/lupus
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for SLE [MIM 152700] and vit-
iligo [MIM 193200])
References
Chakravarti A (1999) Population genetics—making sense out
of sequence. Nat Genet 21:56–60
Reports 1405
Conneally PM, Edwards JH, Kidd KK, Lalouel JM, Morton
NE, Ott J, White R (1985) Report of the Committee on
Methods of Linkage Analysis and Reporting. Cytogenet Cell
Genet 40:356–359
Cottingham RW Jr, Idury RM, Scha¨ffer AA (1993) Faster se-
quential genetic linkage computations. Am J HumGenet 53:
252–263
Das SK, Majumder PP, Chakraborty R, Majumdar TK, Halder
B (1985) Studies on vitiligo. I. Epidemiological profile in
Calcutta, India. Genet Epidemiol 2:71–78
Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B,
Roy-Burman P, Walker A, Mack TM (1992) A revised es-
timate of twin concordance in systemic lupus erythematosus.
Arthritis Rheum 35:311–318
El-Mofti AM (1968) Vitiligo and psoralens. Pergamon Press,
New York
Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA,
Malmgren ML, Rohlf KE, Ockenden TC, Messner RP, King
RA, Rich SS, Behrens TW (1998) A genome-wide search for
susceptibility genes in human systemic lupus erythematosus
sib-pair families. Proc Natl Acad Sci USA 95:14875–14879
Gaffney PM, Ortmann WA, Selby SA, Shark KB, Ockenden
TC, Rohlf KE, Walgrave NL, Boyum WP, Malmgren ML,
Miller ME, Kearns GM, Messner RP, King RA, Rich SS,
Behrens TW (2000) Genome screening in human systemic
lupus erythematosus: results from a second Minnesota co-
hort and combined analyses of 187 sib-pair families. Am J
Hum Genet 66:547–556
Gray-McGuire C, Moser KL, Gaffney PM, Kelly J, Yu H,
Olson JM, Jedrey CM, Jacobs KB, Kimberly RP, Neas BR,
Rich SS, Behrens TW, Harley JB (2000) Genome scan of
human systemic lupus erythematosus by regression model-
ing: evidence of linkage and epistasis at 4p16-15.2. Am J
Hum Genet 67:1460–1469
Grimes PE, Sevall JS, Vojdani A (1996) Cytomegalovirus DNA
identified in skin biopsy specimens of patients with vitiligo.
J Am Acad Dermatol 35:21–26
Hochberg MC (1997) The epidemiology of systemic lupus er-
ythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus
erythematosus. Williams & Wilkins, Baltimore, pp 49–65
Howitz J, Brodthagen H, Schwartz M, Thomsen K (1977)
Prevalence of vitiligo: epidemiological survey of the isle of
Bornholm, Denmark. Arch Dermatol 113:47–52
James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman
TJA, Harley JB (1997) An increased prevalence of Epstein-
Barr virus infection in young patients suggests a possible
etiology for systemic lupus erythematosus. J Clin Invest 100:
3019–3026
James JA, Neas BR, Glass DN, Harley JB (2001) Systemic lupus
erythematosus (SLE) in adults associated with previous Ep-
stein-Barr virus exposure. Arthritis Rheum 44:1122–1126
Kong A, Cox NJ (1997) Allele-sharing models: LOD scores
and accurate linkage tests. Am J Hum Genet 61:1179–1188
Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Para-
metric and nonparametric linkage analysis: a unified mul-
tipoint approach. Am J Hum Genet 58:1347–1363
Lander ES (1996) The new genomics: global views of biology.
Science 274:536–539
Larner AB (1959) Vitiligo. J Invest Dermatol 32:285–310
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT,
Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder
GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998)
Estimates of the prevalence of arthritis and selected mus-
culoskeletal disorders in the United States. Arthritis Rheum
41:778–799
Li YL, Yu CL, Yu HS (2000) IgG anti-melanocyte antibodies
purified from patients with active vitiligo induce HLA-DR
and intercellular adhesion molecule-1 expression and an in-
crease in interleukin-8 release by melanocytes. J Invest Der-
matol 115:969–973
Lindqvist AK, Steinsson K, Johanneson B, Kristjansdottir H,
Arnasson A, Grondal G, Jonasson I, Magnusson V, Sturfelt
G, Truedsson L, Svenungsson E, Lundberg I, Terwilliger JD,
Gyllensten UB, Alarcon-RiquelmeME (2000) A susceptibility
locus for human systemic lupus erythematosus (hSLE1) on
chromosome 2q. J Autoimmun 14:169–178
Magnusson V, Lindqvist AK, Castillejo-Lopez C, Kristjans-
dottir H, Steinsson K, Grondal G, Sturfelt G, Truedsson L,
Svenungsson E, Lundberg I, Gunnarsson I, Bolstad AI, Haga
HJ, Jonsson R, Klareskog L, Alcocer-Varela J, Alarcon-Se-
govia D, Terwilliger JD, Gyllensten UB, Alarcon-Riquelme
ME (2000) Fine mapping of the SLEB2 locus involved in
susceptibility to systemic lupus erythematosus. Genomics
70:307–314
Majumder PP (1993) Segregation analysis in the understanding
of complex human disorders: some recent developments. In:
Majumder PP (ed) Human population genetics: a centennial
tribute to J.B.S. Haldane. Plenum Press, New York, pp 139–
152
Majumder PP, Das SK, Li CC (1988) A genetical model for
vitiligo. Am J Hum Genet 43:119–125
Majumder PP, Nath SK (1992) Statistical analysis of family
data on complex disorders in man. J Genet 71:89–103
Majumder PP, Noedland JJ, Nath SK (1993) Pattern of familial
aggregation of vitiligo. Arch Dermatol 129:994–998
McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J,
Hoffman L, Burgess J, et al (2001) Localization of a sus-
ceptibility gene for familial nonmedullary thyroid carcino-
ma to chromosome 2q21. Am J Hum Genet 69:440–406
Meng W, Shen F, Hu Y (1996) A study on model of inheritance
of systemic lupus erythematosus in Chinese. Zhonghua Yu
Fang Yi Xue Za Zhi 30:30–32 [in Chinese]
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman
K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et
al (1994) A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science 266:66–71
Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C,
Asundi N, Bruner GR, Fox J, Kelly J, Henshall S, Bacino
D, Dietz M, Hogue R, Koelsch G, Nightingale L, Shaver T,
Abdou NI, Albert DA, Carson C, Petri M, Treadwell EL,
James JA, Harley JB (1998) Genome scan of human systemic
lupus erythematosus: evidence for linkage on chromosome
1q in African-American pedigrees. Proc Natl Acad Sci USA
95:14869–14874
Nath SK, Majumder PP, Nordlund JJ (1994) Genetic epide-
miology of vitiligo: multilocus recessivity cross-validated.
Am J Hum Genet 55:981–990
——— (1995) Pedigree analysis of vitiligo: further support for
multilocus involvement. J Genet 74:41–46
1406 Am. J. Hum. Genet. 69:1401–1406, 2001
Nordlund JJ (1987) Hypopigmentation, vitiligo, andmelanoma:
new data, more enigmas. Arch Dermatol 123:1005–1008
Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V
(1998) High frequency of skin-homing melanocyte-specific
cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med
188:1203–1208
Olson JM (1999) Relationship estimation by Markov-process
models in a sib-pair linkage study. Am J Hum Genet 64:
1464–1472
Petri M (1998) The effect of race on incidence and clinical
course in systemic lupus erythematosus: The Hopkins Lupus
Cohort. J Am Med Womens Assoc 53:9–12
Siemens HW (1953) Die Zwillingspathologie der Vitiligo. Acta
Genet Med Gemellol 2:118–124
Vyse TJ, Todd JA (1996) Genetic analysis of autoimmune dis-
ease. Cell 85:311–318
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J,
Collins N, Gregory S, Gumbs C, Micklem G (1995) Identi-
fication of the breast cancer susceptibility gene BRCA2. Na-
ture 378:789–792
